Company Overview

AOA Dx (YC W21) develops AI-powered blood tests for early cancer detection, starting with ovarian cancer screening that achieves over 90% accuracy validated across approximately 1,000 real-world patient samples. The company has raised $32M in total funding, generates $5.4M in annual revenue with 36 employees, and offers its AKRIVIS GD™ test to healthcare providers while conducting the OVERT clinical trial to advance early cancer diagnostics through proprietary lipidomics-based biomarkers.

Revenue
$32M
Loading News...
Loading Timeline...
Loading Culture...
Loading Leadership...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Strong Challenger

AOA Dx is an established challenger with significant market presence and competitive offerings in Healthcare.

Frequently Asked Questions

AI Visibility Rankings

How AOA Dx performs in AI search results

AI Rank
?
Track your position
Platforms
5
ChatGPT, Gemini, Claude...
Visibility
?
Your mention rate
Premium Feature

Unlock AI Visibility Tracking for AOA Dx

See exactly how AOA Dx ranks across ChatGPT, Gemini, Perplexity, Claude, and Grok. Get actionable insights to improve your AI search performance.

Real-time Rankings
Track your position daily
Competitive Intel
See how you compare
Platform Breakdown
Per-AI performance
Actionable Insights
Optimize your visibility
Start Tracking for Free

Join 1,000+ brands · Free 7-day trial · No credit card required

Want to improve your AI visibility? Track performance across all major AI platforms.
Compare with Other Brands

Compare with Other Brands

See how AOA Dx stacks up against competitors with our detailed comparison tool.

Start Comparison